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Aims: The metabolic state of human adults is associated with their gut microbiome. The symbi-
osis between host and microbiome is initiated at birth, and early life microbiome perturbation
can disturb health throughout life. Here, we determined how beneficial microbiome interven-
tions in early life affect metabolic health in adulthood.
Methods: Postnatal diets were supplemented with either prebiotics (scGOS/lcFOS) or synbio-
tics (scGOS/lcFOS with Bifidobacterium breve M-16 V) until post-natal (PN) day 42 in a well-
established rodent model for nutritional programming. Mice were subsequently challenged with
a high-fat Western-style diet (WSD) for 8 weeks. Body weight and composition were moni-
tored, as was gut microbiota composition at PN21, 42 and 98. Markers of glucose homeostasis,
lipid metabolism and host transcriptomics of 6 target tissues were determined in adult-
hood (PN98).
Results: Early life synbiotics protected mice against WSD-induced excessive fat accumulation
throughout life, replicable in 2 independent European animal facilities. Adult insulin sensitivity
and dyslipidaemia were improved and most pronounced changes in gene expression were
observed in the ileum. We observed subtle changes in faecal microbiota composition, both in
early life and in adulthood, including increased abundance of Bifidobacterium. Microbiota trans-
plantation using samples collected from synbiotics-supplemented adolescent mice at PN42 to
age-matched germ-free recipients did not transfer the beneficial phenotype, indicating that
synbiotics-modified microbiota at PN42 is not sufficient to transfer long-lasting protection of
metabolic health status.
Conclusion: Together, these findings show the potential and importance of timing of synbiotic
interventions in early life during crucial microbiota development as a preventive measure to
lower the risk of obesity and improve metabolic health throughout life.
KEYWORDS
body composition, dietary intervention, insulin resistance, liver, mouse model, obesity
therapy
1 | INTRODUCTION
Obesity is a multifactorial condition of pandemic dimensions,1 which is
often accompanied by perturbation of glucose and lipid homeostasis,
together increasing the risk of developing type 2 diabetes mellitus,
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cardiovascular disease and fatty liver disease.2,3 In addition to diet and
other environmental factors, gut microbiota has been linked to the met-
abolic health status of an individual.4,5 Concurrent with host physiology,
the gut microbiota develops dynamically in the first years of life and is
shaped by intrinsic and extrinsic factors, with nutrition playing a signifi-
cant role.6 It is now commonly accepted that nutrition in early postnatal
life has a pronounced impact on lifelong metabolic health,7–9 often
referred to as nutritional programming. For instance, breastfed children
have a higher abundance of bifidobacteria and a lower risk of developing
obesity, glucose intolerance and hypercholesterolaemia as adults com-
pared with formula-fed infants.10–13 Exposure to antibiotics in early life
perturbs development of the gut microbiota, reduces Bifidobacterium
abundance14 and predisposes infants to developing obesity later in
life.15,16 These studies unlock the potential of altering gut microbiota
beneficially in early life to counteract the development of obesity and
metabolic disease later in life.
Pre-, pro- and synbiotics are known to affect gut microbiota com-
position beneficially.17–20 For example, short-chain galacto-
oligosaccharides (scGOS), long-chain fructo-oligosaccharides (lcFOS) as
prebiotics or in combination with Bifidobacterium breve M16 V as a syn-
biotic increase bifidobacteria abundance in infants.21–24 Furthermore,
pre-, pro- and synbiotics are indicated to improve the host’s growth and
metabolic health by microbiota-induced mechanisms,25 but their long-
term effects on the host’s metabolic health beyond intervention have
not been well studied. Therefore, we tested whether nutritional inter-
vention with these components early in life lessens the subsequent
development of diet-induced obesity and affects long-term metabolic
health in the host by supplementing with scGOS/lcFOS alone as a pre-
biotic or in combination with Bifidobacterium breve M16 V as a synbiotic
in a well-established nutritional programming rodent model.26,27
2 | METHODS
All experimental procedures in this study were in accordance with
the principles of good laboratory animal care and practice, and com-
plied with national legislation, following the EU-guidelines for the
protection of animals used for scientific purposes, and were reviewed
and approved by the Animal Experimental Committee DEC-Consult
in Bilthoven, The Netherlands (Study 1) and the Ethics Committee on
Animal Care and Use in Gothenburg, Sweden (Study 2).
At 2 independent European locations, we investigated whether
nutritional pre- and synbiotics protect mice against diet-induced obesity
in our nutritional programming model, as depicted in Figure 1A (Study 1)
and Figure S2A (Study 2). On postnatal day (PN) 2, offspring from
C57BL/6 J dams were randomly culled to 4 male and 2 female pups per
litter, and lactating dams were assigned AIN-93G-based intervention
diets supplemented with prebiotics (PRE: 2% w/w scGOS/lcFOS; Study
1 only), synbiotics (SYN: 2% w/w scGOS/lcFOS+109 CFU/g Bifidobacter-
ium breve M-16 V [Morinaga Milk Industries Ltd., Tokyo, Japan]) or a
non-active control component (REF and CTRL: 2% w/w maltodextrin). In
addition to dietary supplementation, pups received daily (PN10–15) an
oral dose of approximately 10 to 15 mg/day maltodextrin or scGOS/
lcFOS, with or without 1 × 109 cfu B. breve M-16V of their respective
supplement. After weaning (PN21), male offspring were housed in pairs
and continued respective intervention diets until PN42. Thereafter CTRL,
PRE and SYN animals received a Western-style diet (WSD, 40% energy
from fat) as a challenge until sacrifice on PN98. A non-supplemented,
non-WSD-challenged group (REF) served as a normal healthy reference.
Throughout the experiments, body weight and composition were deter-
mined, using either DEXA (Study 1) or MRI (Study 2), and faecal samples
were collected on PN21, 42 and 98. On PN98, animal length was deter-
mined and blood plasma, white adipose tissue (WAT) depots, back-hind
muscles, liver and intestinal segments were collected, weighed, snap fro-
zen and stored at −80 C until further analysis.
Cecal contents of CTRL and SYN mice collected at PN42 in
Study 2 were transplanted to age-matched germ-free C57BL/6 male
recipients that were maintained on WSD for 8 weeks, and their body
weight and composition were determined (Figure 5A).
Fasting total cholesterol, triglycerides, beta-hydroxybutyrate, lep-
tin, insulin and glucose were measured in plasma. Total triglyceride
and cholesterol content were also measured in liver. RNA from duo-
denum, jejunum, ileum, colon, liver and WAT was extracted and
hybridized to Affymetrix GeneChip Mouse Gene 1.1 ST microarrays.
Gene expression was analysed using a Bioconductor software
package-based pipeline.28 Faecal microbiota composition was profiled
by 16S rRNA gene sequencing using an Illumina MiSeq platform and
data were analysed using the QIIME pipeline. Differentially abundant
genera were identified based on negative binomial distribution (Wald
test) using DESeq2 package in the R.
Detailed information related to study conduct, diets, sample col-
lection and data analysis are available online in Appendix S1.
3 | RESULTS
3.1 | Early life synbiotics induce long-term
protection against diet-induced obesity
To explore whether modulating the gut microbiota in early life may
have beneficial effects on metabolism in adulthood, we supplemented
mouse diets with prebiotics (PRE; short chain galacto-oligosaccharides
[scGOS], long chain fructo-oligosaccharides [lcFOS], ratio 9:1) or syn-
biotics (SYN; same as PRE plus Bifidobacterium breve M-16V) (Study1)
(Figure 1A) after birth until PN42. Subsequently, mice were fed a
Western-style diet (WSD) until PN98 and compared to mice that did
not receive early life nutritional supplementation (CTRL). Early life nutri-
tional supplementation did not affect developmental growth during the
intervention period; no significant difference in body weight (P = .174),
fat mass (P = .059), lean body mass (P = .097) (Figure 1B-D) or adipos-
ity (P = .324) (Figure S1) was observed between any of the groups at
PN42. There were also no differences between groups in lean body
mass development under WSD challenge (diet*time interaction,
P = .541) (Figure 1D) or in animal length at PN98 (P = .109) (Table S1),
indicating a normal growth trajectory. The effectiveness of the WSD
challenge was confirmed by accelerated weight gain (diet*time interac-
tion P < .001) and increased fat disposition (diet*time interaction
P < .001) in the CTRL group compared with non-supplemented, non-
challenged healthy reference mice (REF) (Figure 1B,C).
We observed that early life synbiotics supplementation protected
mice against diet-induced obesity, as the SYN group had significantly
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FIGURE 1 Early life synbiotics prevent excessive fat accumulation under WSD challenge. A, Schematic overview of Study1. Litters were culled
at postnatal day (PN) 2 and were randomly divided into 4 diet groups: Reference (REF) and Control (CTRL) groups receiving AIN-G (standard
semi-synthetic diet appropriate for breeding) plus control component (maltodextrin); the PRE group receiving AIN-G supplemented with
prebiotics (scGOS/lcFOS in ratio 9:1); and the SYN group receiving AIN-G, supplemented with synbiotics (scGOS/lcFOS in a ratio 9:1 + B. breve
M-16V) until PN42. At PN42, the REF group was maintained on AIN-M (semi-synthetic diet appropriate for maintenance) and the CTRL, PRE
and SYN groups were challenged with Western-style diet (40% energy from fat) until PN98. Body weight (B), fat mass (C) and lean body mass
(D) in the REF (n = 8), CTRL (n = 7), PRE (n = 9) and SYN (n = 11) groups of mice at PN42, PN70 and PN98. Sum of fat pads (E) and plasma
leptin level (F) in the REF (n = 8), CTRL (n = 7), PRE (n = 9) and SYN (n = 11) groups of mice at PN98. Data are given as mean  SEM. In (B) to
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reduced body weight and fat mass compared with the CTRL and PRE
groups, both at PN70 (SYN vs CTRL, PBW = .012, PFM < .001; SYN vs
PRE, PBW = .007, PFM = .014) and PN98 (SYN vs CTRL, PBW = .004,
PFM < .001; SYN vs PRE, PBW = .002, PFM < .001) (Figure 1B,C). In
accordance with this observation, average fat mass percentage was
reduced in the SYN group compared with the CTRL group at PN70
(P = .001) and PN98 (P = .002) (Figures S1B and S1C). Food intake
did not differ between groups (data not shown).
Synbiotic supplementation also reduced individual fat pad weights
(Table S1) and the sum of fat pad weights (P = .036) at PN98 in the
SYN group compared with the CTRL group (Figure 1E). In agreement
with reduced adiposity, we observed that plasma leptin was reduced in
the SYN group compared with the CTRL group (Figure 1F). In contrast,
body weight, fat mass, fat pad weights and leptin level did not differ sig-
nificantly at any time point in the PRE group compared with the CTRL
group, suggesting that PRE is more effective in combination with the
probiotic component in protecting against diet-induced obesity.
To test the robustness of the findings, the study was repeated in
a second animal facility in another European country, and the results
on body weight and adipose phenotype (Study 2) (Figure S2A) were
reproduced. Synbiotic supplementation reduced both body weight
(P = .031) and fat mass (P = .026) compared with the CTRL group at
PN98 (Figures S2B and S2C). Lean body mass remained similar in the
SYN and CTRL groups throughout the experiment (PPN70 = .652,
PPN98 = .914), reflecting normal growth (Figure S2D). Thus, it seems
that the beneficial long-term effects of synbiotic supplementation in
early life are independent of environmental conditions that may differ
between animal facilities.
3.2 | Early life synbiotics improve glucose and lipid
metabolism in adulthood
To address whether protection from obesity was also associated with
improved metabolic parameters, we determined the HOMA-IR index
as a surrogate marker for insulin resistance and found that the SYN
group showed a trend towards reduced HOMA-IR (P = .067) compared
with the CTRL group (Figure 2A), suggesting improved insulin sensitiv-
ity. This effect was driven mainly by reduced insulin levels (P = .039) in
the SYN group compared with the CTRL group (Figure 2B), whereas
fasting glucose levels were similar between groups (Figure 2C). While
plasma levels of triglycerides (TG) were similar in all WSD-challenged
groups (P = .986) (Figure 2D), we observed that total plasma choles-
terol was significantly reduced in the SYN group compared with the
CTRL group (P = .003), resembling REF group levels (Figure 2E). In
addition, we detected increased plasma levels of beta-hydroxybutyrate
(P = .047) in the SYN group compared with the CTRL group
(Figure 2F), indicating higher fatty acid oxidation, which might contrib-
ute to protection against obesity and improved glucose metabolism.
The improvement in adult plasma parameters following early life
synbiotic supplementation was also associated with reduced liver weight
(SYN vs CTRL, P = .017; SYN vs PRE, P = .016) and decreased hepatic
TG content (SYN vs CTRL, P = .034; SYN vs PRE, P = .009) (Figure 2G
and H). These data suggest that the protective effect of synbiotic sup-
plementation against obesity is accompanied by improvements in
metabolism, including parameters of glucose and lipid homeostasis.
3.3 | Early life synbiotics alter cholesterol
metabolism in the ileum in adulthood
To explore potential molecular mechanisms underlying the beneficial
long-term effects of early life synbiotic supplementation compared
with the CTRL group, we performed microarray analysis of 6 relevant
tissues harvested on PN98: duodenum, jejunum, ileum and colon,
liver and white adipose tissue. We observed that 144 genes were dif-
ferentially regulated (q ≤ .05) in ileum in the SYN vs CTRL compari-
son. Of these 144 genes, 57% were relatively less expressed in the
SYN group compared with the CTRL group. In contrast, other tissues
did not show differentially expressed genes after FDR adjustment in
the SYN vs CTRL comparison, indicating that synbiotic supplementa-
tion in early life has the most pronounced effects on ileal gene
expression in adulthood. Additional information on all differentially
expressed genes and their functions in the ileum, as defined by the
Gene Ontology (GO) Database, is provided online in Table S2.
To identify regulated biological functions and canonical path-
ways in the ileum for SYN vs CTRL comparison, we performed
Ingenuity Pathway Analysis (IPA) on differentially expressed genes
(q ≤ .05). “Lipid metabolism” was identified as one of the strongest
regulated biological functions in the ileum of adult mice supplemen-
ted with synbiotics in early life compared with the CTRL group
(Figure 3A). In agreement with this, the 4 most strongly regulated
canonical pathways (Figure 3B) were: “LPS/IL-1 mediated inhibition
of RXR,” related to the regulation of lipid, cholesterol and xenobi-
otic metabolism, “Superpathway of cholesterol biosynthesis,”
“Zymosterol Biosynthesis,” feeding into cholesterol biosynthesis and
“LXR/RXR activation,” which is also related to lipid and cholesterol
metabolism. This suggests that lipid and cholesterol metabolism are
the most strongly regulated functions in adult mice following syn-
biotic supplementation in early life. Following this lead, we selected
gene sets related to cholesterol metabolism and fate, including cho-
lesterol biosynthesis, esterification, transport, distribution and regu-
lation. The expression level of respective genes (n = 31), displayed
as signal intensity per sample normalized to the mean signal of the
CTRL group, is shown in the heatmap in Figure 3C, highlighting that
the effects are strongest in SYN samples compared to the CTRL
group. We observed that 6 of the selected 31 genes were signifi-
cantly (q ≤ .05) regulated in SYN vs CTRL comparison, while other
genes followed the same trend of regulation as indicated in the
heatmap (Figure 3C). Gene sets related to cholesterol biosynthesis,
that is, mevalonate pathway and steroid biosynthesis (Hmgcs1,
Pmvk, Tm7sf2, Msmo1 and Nsdhl with q ≤ 0.05) and cholesterol
uptake into the cell were up-regulated in adult mice with synbiotic
supplementation in early life compared with the CTRL group
(Figure 3C,D and Table S3). In contrast, genes related to cholesterol
storage, distribution and excretion, including Abca1 (q = 0.038),
were down-regulated in the SYN group vs the CTRL group
(Figure 3C,D and Table S3). Taken together, synbiotic supplementa-
tion in early life induced the expression of genes involved in intesti-
nal cholesterol synthesis and uptake in ileal cells of adult mice
compared with CTRL mice receiving WSD. These observations for
the SYN vs CTRL groups were largely in line with the effects in the
REF vs CTRL groups (Figure 3C).
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3.4 | Early life synbiotics intervention induces subtle
microbiota changes
The microbiota composition of faecal samples collected at PN21,
PN42 and PN98 was determined using Illumina MiSeq platform. In
total, we generated 4 176 221 sequences with a mean  SD of
42 184  6391 sequences per sample. To investigate the variance
within and between groups, weighted unifrac distances (sensitive to
abundance of taxa) were obtained. We observed no significant
difference in distances within the individual groups or between
groups, or between distances within and between groups (Figure 4A).
Alpha diversity, which reflects within sample diversity, measured by
“observed species,” was significantly higher in the SYN group com-
pared with the PRE (P = .042) and CTRL (P = .006) groups at PN21
and PN42, respectively (Figure 4B), indicating that synbiotic supple-
mentation increased early life faecal bacterial diversity.
To determine the overall microbiota structure over time, we ana-
lysed the microbiota composition at phylum level. The abundance of
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Firmicutes reduced in the SYN group compared with the CTRL and
PRE groups at PN42 (Figure 4C). Synbiotic supplementation trended
towards increasing the abundance of Actinobacteria at PN42 and
reached statistical significance at PN98 compared with the CTRL
group (Figure 4C). At PN98, the abundance of Bacteroidetes was sig-
nificantly reduced in the SYN group compared with the CTRL group,
while the level of Firmicutes did not differ between these groups
(Figure 4C). Levels of abundant genera that differed across different
time points were plotted in Figure 4D-F to explain observed pheno-
typic differences between the groups. The abundance of Bifidobacter-
ium was highest in the synbiotic-supplemented group compared with
the CTRL group at PN21 (Figure 4D). Moreover, a higher proportion
of Bifidobacterium in the SYN group, compared with all other groups
including the PRE group, was maintained until PN98 (Figure 4D). The
level of Lactobacillus fluctuated at different time points and was not
significantly altered in the SYN group compared with the CTRL group
at any time point (Figure 4E). The relative abundance of unidentified
genus from family S24_7, belonging to phylum Bacteroidetes,
increased in the SYN group compared with the CTRL group at PN42,
but decreased at PN98 (Figure 4F). We also identified differentially
abundant genera that were altered in the SYN vs CTRL comparison
at different time points, using negative binomial generalized linear
models (Figure S3). Interestingly, a low-abundance unidentified genus
from Alphaproteobacteria (order RF32) was identified as the most
differentially abundant genus, with higher levels in the SYN group
compared with the CTRL group at all 3 time points (Figure S3A). At
PN42, Lactobacillus was identified with logFC = −1.40 (Figure S3A),
consistent with its trend of lower abundance in the SYN group com-
pared with the CTRL group (Figure 4E). In addition, Dorea (logFC =
4.31) and Parabacteroides (logFC = −1.67) were also identified at
PN42 (Figure S3A).
Next, we performed sequencing of the samples obtained in the
second facility (Study 2) at PN21, PN42 and PN98 (Figure S3), using
the same protocol. Weighted unifrac distances revealed that distance
within the SYN group was significantly reduced from that in the
CTRL vs SYN and SYN vs REF comparison at PN21, and the SYN vs
REF comparison at PN98 (Figure S4A), indicating altered bacterial
composition. Alpha diversity did not differ between groups
(Figure S4B). At phylum level, there was a reduction in abundance of
Bacteroidetes with no difference in levels of Firmicutes in SYN mice
compared with CTRL mice at PN98 (Figure S4C). The relative abun-
dance of Bifidobacterium was higher in the SYN group vs the CTRL
group at PN21 (similar to Figure 4D), but it was not maintained at
PN42 and PN98 (Figure S4D). The level of Lactobacillus was reduced
in the SYN group compared with the CTRL group at PN21
(Figure S4E). The relative abundance of unidentified genus from fam-
ily S24_7 increased following SYN supplementation at PN21, but was
not maintained at later time points (Figure S4F). DESeq2 analysis
revealed Bifidobacterium (log FC = 1.35) and an unidentified genus
from family S24_7 (logFC = 1.30) that showed higher levels in the
SYN group compared with the CTRL group at PN21 (Figure S3B),
consistent with data presented in Figure S4D and S4F. Interestingly,
we also identified the low-abundance genus Akkermansia that
showed lower levels at PN21 (logFC = −2.34) and then increased
(logFC = 6.58) at PN98 in the SYN group vs the CTRL group,
probably coinciding with shifts in diet (Figure S3B). Thus, we
observed different taxonomic changes within the microbiota, despite
similar metabolic outcomes of nutritional intervention.
3.5 | Microbiota transplant in adolescence does not
transfer beneficial phenotype of synbiotics
To determine whether the improved adult metabolic phenotype of
SYN mice was mediated by altered microbiota, we colonized 6-week-
old germ-free (GF) mice with cecal content from age-matched CTRL
or SYN donor mice and determined the development of body weight
and body composition under WSD challenge over 8 weeks
(Figure 5A). At the time of transfer (PN42), there were no differences
in body weight, fat mass and lean body mass (P = .996; P > .999;
P = .604, respectively) between recipient GF mice (Figure 5B-D). Fol-
lowing microbiota transfer, we observed no significant differences in
development of body weight (P = .310), fat mass (P = .902) or lean
body mass (P = 0.302) between the CTRL and SYN groups
(Figure 5B-D). Thus, transferring the modified microbiota after syn-
biotic supplementation to age-matched adolescent recipients is not
sufficient to transfer the protected phenotype of synbiotic-
supplemented mice.
4 | DISCUSSION
Perturbation of the gut microbiota in early life by antibiotics has been
shown to promote development of obesity and an adverse metabolic
phenotype later in life.15,16,29 In the present study, we showed that
beneficial modulation of the gut microbiota by early life synbiotics,
consisting of scGOS/lcFOS plus Bifidobacterium breve M16V, but not
by the prebiotic component alone, protected against later-life devel-
opment of diet-induced obesity, reproducibly in 2 different locations.
Early life synbiotics also improved the adult metabolic phenotype and
induced long-term changes in gene expression patterns, specifically in
the ileum, related to lipid and cholesterol metabolism in adult mice.
Although we observed similar metabolic improvements in the 2 vivaria
following synbiotic supplementation, the taxonomic configuration of
the microbiota differed, apart from the similarly increased Bifidobac-
terium abundance in early life. Furthermore, cecal microbiota trans-
plantation from adolescent donors did not transfer the protective
phenotype against diet-induced obesity in age-matched GF recipi-
ents, indicating a critical window of opportunity for the effectiveness
of microbiota modulation. Thus, early synbiotic supplementation
improves metabolic health later in life and affects the gut microbiota.
We did not detect any direct effects of prebiotics or synbiotics
on developmental growth and body composition during the interven-
tion period itself. This is in accordance with previous clinical interven-
tion studies that showed that applied prebiotics and synbiotic blend
support normal growth in healthy full-term infants.30–35 Under mod-
erate WSD challenge following the intervention, we found that the
SYN group was protected against diet-induced excessive fat accumu-
lation and related accelerated weight gain compared with the CTRL
group. In contrast, the prebiotic group did not show protection
against diet-induced obesity. As we did not investigate the effects of
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B. breve M-16V alone, we cannot exclude that the beneficial effects
observed in the SYN group are mainly mediated by the bacterium.
Apart from the knowledge that human milk, containing naturally
occurring pre- and probiotics, is protective against metabolic
disturbances later in life,,11,12,25,36,37 there is only 1 study with a pre-
vention paradigm, showing that early probiotic supplementation in
pregnant mothers and infants for 6 months supports healthy growth
in infants up to 4 years of age,38 which is consistent with our
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findings. Another probiotic intervention in infants during weaning
(at 4-13 months of age) resulted in no beneficial effect on growth
and metabolic parameters,39 indicating the importance of the timing
for effectiveness of dietary supplements. In a treatment setting, how-
ever, there is substantial evidence that pre- and synbiotics can
improve metabolic disorders and support weight loss.40,41
The protection against adult obesity via early life synbiotics was
associated with improved glucose metabolism, decreased hepatic lipid
deposition and attenuated hypercholesterolaemia in adulthood. The
reduced steatosis was associated with increased serum levels of
beta-hydroxybutyrate, suggesting that SYN intervention, in part, acts
by increasing fatty acid oxidation. It is known that pro- and synbiotics
are successful for treatment of fatty liver disease,40,42,43 with intesti-
nal microbiota being indicated in the mode of action.44,45
Our transcriptomic analyses for exploration of molecular long-
term changes induced by early life synbiotic supplementation
revealed the strongest effects on gene expression related to lipid
metabolism in the small intestine in adult mice, which is a major con-
tributor to the cholesterol pool.46,47 In synbiotic-supplemented mice
compared with CTRL mice, we detected a collective activation of
genes related to cholesterol biosynthesis upon WSD challenge in the
ileum, while the expression of genes related to cholesterol excretion,
such as Abca1 was down-regulated. In type 2 diabetic rats, Abca1 is
increased in intestinal epithelial cells.48 Thus, down-regulation of
intestinal Abca1, plus higher intestinal cholesterol synthesis in SYN-
supplemented mice, concurrent with beneficially decreased blood
cholesterol levels, might be an adaptive mechanism to cope with the
higher cholesterol requirement in ileal enterocytes.
Pre-, pro- and synbiotic supplementation is associated with bene-
ficial changes in the gut microbiome in mice49 and humans.22,23,50,51
We observed that early life synbiotics altered the microbiome, with a
significant increase in genus Bifidobacterium at PN21 in both indepen-
dent experiments. This is in line with previous studies advocating
addition of pre- and synbiotic supplements to infant formula.21–24
The bifidogenic effect of our early life synbiotic supplementation may
drive the observed anti-obesity effects, as childhood obesity has been
linked to depletion of the early life bifidobacteria abundance.52,53 For
the prebiotic component alone, whose effect depends on already-
present resident microbes at the time of intervention,17 we did not
observe a bifidogenic effect. It is interesting to note that other taxo-
nomic changes were not similar in the 2 independent locations, but
metabolic phenotypes were reproducible. Furthermore, we showed
with our transplant experiment that transferring the synbiotics-
modified microbial community from adolescent donors (at PN42) to
age-matched GF mice does not confer protection against diet-
induced obesity in recipients. This implicates the importance of the
timing of microbiota modulation; that is, exposure to synbiotics in
early life is relevant for achieving long-lasting beneficial and
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protective metabolic effects. Provided that the gut microbiota dif-
fered between P21 and P42, we cannot exclude that the microbiota
transplant from PN21 donors might have produced a different result.
Nevertheless, our data strengthen the notion of the importance of
breastfeeding and synbiotic supplementation of infant formulas in
early life to promote the bifidogenic effect in infants, thereby improv-
ing metabolism and protecting against metabolic disorders later
in life.
In conclusion, this study adds evidence that early colonization
of the digestive tract by symbiotic microbes may be critical for
healthy metabolic development, and maintenance of a healthy
metabolism in adulthood. With nutritional interventions in a relevant
rodent model, we show that early life synbiotic supplementation
can protect against the development of obesity and metabolic dis-
ease later in life. Obesity in adults and children is on the rise glob-
ally and there is no powerful cure, other than bariatric surgery, for
this worldwide epidemic and its associated metabolic impairments.
Our study provides important insights into the beneficial effects of
supplementation with synbiotics in early life, which may lead to the
development of preventive strategies; however, validation in
humans is warranted.
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